University of Missouri School of Medicine MU Health School of Medicine
News Divider

MU Researchers Find Gene Therapy Protects Mice from Heart Condition


The condition is a leading cause of death for those with Duchenne muscular dystrophy

A new gene therapy developed by researchers at the University of Missouri School of Medicine has shown to protect mice from a life-threatening heart condition caused by muscular dystrophy.

Lai

“This is a new therapeutic avenue,” said Yi Lai, PhD, the leading author of the study and assistant research professor in the MU School of Medicine’s Department of Molecular Microbiology and Immunology. “This is just a first step, but we hope this could lead to a treatment for people with this devastating heart condition, which is a leading cause of death for people with Duchenne muscular dystrophy.”

About one in 3,500 children, mostly boys, are born with Duchenne muscular dystrophy (DMD). They experience a progressive wasting away of muscles, starting in the legs and pelvis. Children with DMD have difficulty walking, and most need wheelchairs by age 12.

As DMD depletes the skeletal muscles, it also causes the heart to decay. A weakened heart kills up to 40 percent of people with DMD, usually by their 20s or early 30s. DMD originates with mutations in a single gene. For more than two decades, researchers have explored using gene therapy, an experimental treatment, to replace the flawed gene with a healthy copy.

Duan
Duan

The recent MU study, however, did not try to replace the faulty gene. The researchers targeted a different gene — one involved with the heart’s built-in system for responding to heart attacks and other emergencies.

This targeted gene expresses a protein called nNOS. During short-term stresses, nNOS activates briefly to help regulate the heart. The MU researchers altered the gene to enable more efficient transfer of the nNOS gene to mouse hearts.

Seven months after the gene therapy, the mice who received the treatment showed significantly improved overall heart health. On most disease indicators, the researchers found that the treatment protected their hearts from the damage of DMD.

“The study showed for the first time that a modified nNOS gene could be delivered through gene therapy to protect the hearts of mice from Duchenne muscular dystrophy,” said Dongsheng Duan, PhD, co-author of the study and Margaret Proctor Mulligan Professor in Medical Research at the MU School of Medicine.

“Since nNOS protects against multiple heart diseases, this method could one day be extended to the treatment of other heart diseases, such as heart failure or a heart attack,” Duan said.

The technique is in an early stage of development and will require more research before potential applications in humans are explored.

The study, “Partial Restoration of Cardiac Function with ∆PDZ nNOS in Aged MDX Model of Duchenne Cardiomyopathy,” was published in June in Human Molecular Genetics. Along with Lai and Duan, other study authors include Junling Zhao, research technician, Yongping Yue, senior research specialist, and Nalinda B. Wasala, graduate student, all of the MU Department of Molecular Microbiology and Immunology.

Click here to download a high resolution portrait of Lai.
Click here to download a high resolution portrait of Duan.

 


Missouri Health News Network

Divider

News and Events

Dermatology Gala Gala To Celebrate Five Decades Of Dermatology At MU
Dermatology residency program began in 1963

HIV MU Researchers Discover Protein's Ability To Inhibit HIV Release
TIM-family proteins also play role in Ebola and other viral infections

McAndrew $2.4 Million Gift Funds Endowed Chair in Cancer Research
Support inspired by experience with cancer center and student at MU

Lai MU Researchers Find Gene Therapy Protects Mice from Heart Condition
The condition is a leading cause of death for those with Duchenne muscular dystrophy

White Coat Ceremony MU's Expanded Medical Class Receives White Coats at Ceremony
Event marks start of professional journey for 104 students

Belden Interactive E-Book Aims to Improve Electronic Health Records
E-book provides guidelines for usability of EHRs

Delafontaine Tulane Cardiovascular Researcher Named School of Medicine Dean
Patrice Delafontaine, MD, is accomplished physician-scientist, educator, administrator

Frederick Fraunfelder, MD Fraunfelder Joins MU School of Medicine as Chair of Ophthalmology
Fraunfelder specializes in corneal disease, cancers of the eye and laser surgery

Karl D. Nolph, MD In Memoriam: Karl D. Nolph, MD
Nephrology leader was pioneer in the field of dialysis

Class of 2014 Race Could Be a Factor in Head and Neck Cancer Survival Rates
Prognosis has not improved for African-Americans




Media Relations
University of Missouri Health System
One Hospital Drive, DC028.00
Columbia, MO 65212
24/7 on-call pager: (573) 876-0708

Mary Jenkins
jenkinsmg@health.missouri.edu
(573) 882-7299

Jeff Hoelscher
hoelscherj@health.missouri.edu
(573) 884-1608

Derek Thompson
thompsonder@health.missouri.edu
(573) 882-3323


Web Communications
University of Missouri Health System
One Hospital Drive, MA204G, DC018.00
Columbia, MO 65212
(573) 884-0298

Rich Gleba
glebar@health.missouri.edu
(573) 884-0298

Laura Gerding, APR
gerdingla@health.missouri.edu
(573) 882-9193

Velvet Hasner
hasnerv@health.missouri.edu
(573) 884-1115

Mike Muin
muinm@health.missouri.edu
(573) 884-7541



Printer Friendly
Follow us on Twitter!   Facebook   YouTube Videos  
Website created and maintained by the Office of Communications.
Contact the MU School of Medicine.
Revised: August 21, 2014 - Copyright © 2013 - The Curators of the University of Missouri System.
All rights reserved. DMCA and other copyright information. An equal opportunity/affirmative action institution.